Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine plus electroconvulsive stimulation in treatment-resistant major depressive disorder
2024-512559-20-00Phase 3Withdrawn
- Sponsor
- Vita-Salute San Raffaele University
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in major depressive disorder (MDD) and treatment-resistant depression (TRD), sponsored by Vita-Salute San Raffaele University. Primary endpoint: Change in MADRS score from baseline to Day 28. Planned start Oct 2024; status: withdrawn.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2024-512559-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512559-20-00.